AFFiRiS AG has begun testing a new vaccine designed to treat Parkinson’s disease. Dubbed PD01A, the vaccine is the first treatment with the potential to focus on the cause of the disease, instead of the symptoms.
PD01A targets alpha-Synuclein (alpha-syn), a protein believed to play a significant role in the development and progression of Parkinson’s. The vaccine is intended to direct the body’s natural immune system to create antibodies that target alpha-syn. It’s believed that reducing the levels of alpha-syn in the brain could alleviate symptoms and alter the course of the disease.
Called “immunotherapy,” this type of treatment strategy has never been used on patients with Parkinson’s disease, and experts are excited about the potential benefits. In fact, the Michael J. Fox Foundation assented 1.5 million dollars in financial support to the development of the vaccine.
What Patients Can Do Now
Unfortunately, the PD01A vaccine is in the earliest stages of clinical trials. This means it could take years before it is made available to desperate Parkinson’s sufferers, who are struggling with all sorts of painful and frustrating symptoms.
Fortunately, you can get help today by contacting Dr. Winber’s office. Many sufferers are shocked to learn that a simple dental appliance can alleviate Parkinson's symptoms, including tremors, facial tics and numbness in the extremities. By adjusting the bite, Dr. Winber provides relief to desperate patients. Contact us online or call (303) 691-0267 today to learn more.